GRACE

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

Retrieved on: 
Dienstag, Mai 28, 2024
ENDO, New Drug Application, Patient, Doctor of Philosophy, Odds ratio, Endocrine Society, Hyperglycemia, Doctor of Pharmacy, DSM-IV codes, MD, Syndrome, Hypertension, HID, Saint Andrew's Society, Physician, GRACE, Pharmaceutical industry

On April 22, Corcept announced that patients in GRACE’s initial, open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other symptoms experienced by patients with Cushing’s syndrome.

Key Points: 
  • On April 22, Corcept announced that patients in GRACE’s initial, open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other symptoms experienced by patients with Cushing’s syndrome.
  • GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo (odds ratio: 0.17; p-value: 0.02).
  • Consistent with its known safety profile, relacorilant was well-tolerated in both phases of GRACE, with no differences in the randomized withdrawal phase between the relacorilant and placebo groups.
  • “The data from GRACE make a compelling case for the use of relacorilant in patients with endogenous hypercortisolism.

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

Retrieved on: 
Montag, April 22, 2024
GRACE, Hyperglycemia, University, Patient, Syndrome, SBP, Adrenal insufficiency, Safety, NDA, Waist, Ann Arbor, Michigan, MD, Doctor of Philosophy, Vaginal bleeding, DSM-IV codes, Doctor of Pharmacy, Diabetes, Hypertension, Metabolism, Internal medicine, Endocrinology, Division, Deficit spending, DBP, Pharmaceutical industry

In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.

Key Points: 
  • In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.
  • GRACE’s primary endpoint is maintenance of blood pressure control in the “randomized withdrawal” phase, with maintenance of glycemic control as the key secondary endpoint.
  • Other key secondary and exploratory endpoints in the randomized withdrawal phase include changes in weight, waist circumference, cognitive impairment and Cushing’s Quality of Life score.
  • Patients in the open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints.

Aqueduct Technologies Elevates GRC Programs with GRACE 2.0 Platform Release

Retrieved on: 
Donnerstag, April 4, 2024
ROI, Organization, Risk management, Risk, Policy, GRACE, Risk assessment, Computer security, GRC, Customer advisory council

CANTON, Mass., April 4, 2024 /PRNewswire/ -- Aqueduct Technologies, a leading IT solutions provider, announced the general availability of GRACE 2.0 , the latest iteration of its Governance, Risk, and Compliance (GRC) Program.

Key Points: 
  • CANTON, Mass., April 4, 2024 /PRNewswire/ -- Aqueduct Technologies, a leading IT solutions provider, announced the general availability of GRACE 2.0 , the latest iteration of its Governance, Risk, and Compliance (GRC) Program.
  • The latest release includes cutting-edge features to streamline how customers manage compliance, frameworks, and risk within their organization.
  • GRACE (Governance, Risk, and Compliance Engine) serves as the cornerstone of Aqueduct's GRC Program, providing a centralized hub for resource allocation, policy management, risk assessment, control mapping, and more.
  • Key features of the GRACE 2.0 release include:
    Crosswalk Functionality: Empowers users to seamlessly crosswalk 30+ frameworks by consolidating thousands of controls and sub-controls into a unified set mapped to all relevant frameworks.

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Februar 15, 2024
Woman, ALS, Oncology, PIN, MD, Investment, Physician, Neuroinflammation, Syndrome, Exercise, GRACE, Doctor of Pharmacy, Prevalence, Ovarian cancer, Patient, Journal, NASH, Atrophy, NDA, Glomus tumor, Pharmaceutical industry

Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism.

Key Points: 
  • Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism.
  • Corcept’s fourth quarter 2023 revenue was $135.4 million, compared to $103.1 million in the fourth quarter of 2022.
  • Diluted net income per common share was $0.28 in the fourth quarter of 2023, compared to $0.14 in the fourth quarter of 2022.
  • Cash and investments were $425.4 million at December 31, 2023 compared to $436.6 million at December 31, 2022.

$20 Million Donation to Howard University Supports GRACE Grant Program

Retrieved on: 
Montag, Dezember 11, 2023
FACS, EFC, Student, Pell, MBA, Graduation, Education, Federation, University, Denver Broncos, Face, GRACE, Howard University, Child, Nursing

WASHINGTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- A $20 million donation to Howard University from Carrie Walton Penner and Greg Penner will support the GRACE Grant Endowed Fund, an initiative to eliminate college costs and keep first-year students enrolled through graduation.

Key Points: 
  • WASHINGTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- A $20 million donation to Howard University from Carrie Walton Penner and Greg Penner will support the GRACE Grant Endowed Fund, an initiative to eliminate college costs and keep first-year students enrolled through graduation.
  • The GRACE (Graduation Retention Access to Continued Excellence) Grant program provides a 100% match to first-time undergraduate students who receive the maximum Pell Grant from the federal government, with additional funds available to students who have an expected family contribution (EFC) of $0.
  • The average four-year graduation rate for EFC $0 GRACE recipients is 42 percent higher than those in the same category who did not receive GRACE funds.
  • “The GRACE Grant program empowers students during a crucial moment in their academic lives through to college graduation.”
    Carrie and Greg added that they hope their support for the GRACE Grant program encourages others to do the same.

Sam’s Club Announces Reopening in Grapevine, Texas

Retrieved on: 
Mittwoch, Dezember 13, 2023
Philanthropy, Retail, Other Retail, Discount, Variety, Other Philanthropy, Supermarket, Food, Beverage, Club, Community Exchange System, City, Sam, GRACE, Sam's Club, Plus, Commerce, Multimedia, Walmart, EVP, Dallas–Fort Worth metroplex, Nightclub, Vitis

View the full release here: https://www.businesswire.com/news/home/20231213273242/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213273242/en/
    Rendering of the Grapevine, Texas Sam's Club that is planned to reopen in late 2024.
  • (Photo: Business Wire)
    Following extensive renovations, Sam's Club is eager to reintroduce an enhanced shopping experience to its valued members.
  • We look forward to collaborating with Sam's Club as they begin the reopening process to support our business community and enhance the shopping experience for all."
  • The reopening of the Grapevine Sam's Club is expected to make an impact on the local economy by creating additional job opportunities.

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Mittwoch, November 1, 2023
American Journal of Clinical Oncology, Ovarian cancer, PIN, Physician, Prevalence, MD, GRACE, Journal, Metabolism, Glomus tumor, NASH, ALS, Doctor of Pharmacy, Syndrome, NDA, Investment, Patient, CORT, Pharmaceutical industry, Cryptocurrency, Medical device

We are raising our 2023 revenue guidance again, to $470 - $480 million,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.

Key Points: 
  • We are raising our 2023 revenue guidance again, to $470 - $480 million,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
  • Corcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022.
  • Net income was $31.4 million in the third quarter of 2023 compared to $34.6 million in the same period last year.
  • Cash and investments were $414.8 million at September 30, 2023 compared to $363.3 million at the end of the prior quarter.

H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development

Retrieved on: 
Donnerstag, Oktober 19, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Knowledge, Massachusetts General Hospital, SMMT, Harvard Medical School, Publishing, City of Hope, Medical director, Lung cancer, GRACE, Drug, Summit, Quality of life, City, Global resources dividend, Providence Health & Services, Medscape, University, Therapy, Patient, Hospital, UpToDate, Associate, Pharmaceutical industry, Medical device, Nursing, MD

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.
  • West brings a wealth of experience, and his knowledge in treating lung cancer patients is unrivaled,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of the Company.
  • We are thrilled to welcome Jack to our team.”
    Dr. West joins Summit from City of Hope, one of the nation’s leading cancer treatment and research centers.
  • As a practicing physician, Dr. West has been a principal investigator in over 20 clinical trials in lung cancer.

GUINNESS WORLD RECORDS 2024 Edition Released

Retrieved on: 
Donnerstag, September 14, 2023
Yoga, Hot, Young Achievers Award, Basketball, Male, Hair, BLUE, Human, Partnership, Tennis, Horns, Ninja, GUINNESS, GRACE, SCIENCE, Mammal, Clothing, Guinea, Record, The Care Bears Movie, Guinness, ARTS, Ship, GWR, Science, Guinness World Records, Athlete, Sasuke (TV series), Grace, Care Bears, Collection, Hula, Water, AMIR, Travel, Football, Rest, Book, Calf, Lake, Nightclub, Film industry, Entertainment, Jewellery, Rolling (metalworking), Amusement park, Video game, Jurassic Park

NEW YORK, Sept. 14, 2023 /PRNewswire/ -- GUINNESS WORLD RECORDS (GWR), the global authority on record-breaking achievements, announces that GUINNESS WORLD RECORDS™2024 (GWR2024) is available in stores and online today. The new edition includes 2,638 mind-blowing achievements from around the world.

Key Points: 
  • NEW YORK, Sept. 14, 2023 /PRNewswire/ -- GUINNESS WORLD RECORDS (GWR), the global authority on record-breaking achievements, announces that GUINNESS WORLD RECORDS™2024 (GWR2024) is available in stores and online today.
  • GUINNESS WORLD RECORDS 2024 is available for purchase in stores and online from Sept. 14, 2023.
  • Completing the illustrated Guinness World Records universe, the artwork takes the reader on a deep-sea odyssey to the bottom of the ocean.
  • GUINNESS WORLD RECORDS 2024 is available for purchase in stores and online from Sept. 14, 2023, with discounts widely available.

GENESIS AND THE COUNCIL OF FASHION DESIGNERS OF AMERICA ANNOUNCE THREE RISING DESIGNERS FOR DESIGN + INNOVATION GRANT

Retrieved on: 
Mittwoch, September 6, 2023
Heart, G90, Council of Fashion Designers of America, Genesis G80, Partnership, CFDA, Life, Culture, GRACE, G70, Mentorship, Carbon, Creativity, Fashion, G80, AAPI, GV70, Collection, Showroom, Council, Restaurant, Genesis GV70, House, Safety, Electrification, Fashion design, Studio, Genesis

NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Today, Genesis and the Council of Fashion Designers of America (CFDA) announced the selection of three designers who will compete for the CFDA | Genesis House AAPI Design + Innovation Grant, unveiled earlier this summer.

Key Points: 
  • NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Today, Genesis and the Council of Fashion Designers of America (CFDA) announced the selection of three designers who will compete for the CFDA | Genesis House AAPI Design + Innovation Grant, unveiled earlier this summer.
  • The designers will also be given a $40,000 grant from Genesis to fund their collections.
  • "We are so thrilled with the three participating designers in the CFDA I Genesis House AAPI Design + Innovation Grant program," CFDA CEO Steven Kolb said.
  • Genesis has stated its commitment to becoming an all-electric vehicle brand by 2030 and to pursuing carbon neutrality by 2035.